Volume 1, Issue 2, July 2022

View Volume 1, Issue 2, July 2022

Immunotherapy in Hodgkin lymphoma: Current and evolving roles
Tailoring therapy in Waldenström Macroglobulinemia
Multiple myeloma management: What comes after lenalidomide-based therapy?
Chimeric antigen receptor T-cell therapy for relapsed and refractory large B-cell lymphoma: A Canadian perspective
With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL)

Published: 2022-07-01

Articles

Chimeric antigen receptor T-cell therapy for relapsed and refractory large B-cell lymphoma A Canadian perspective

Mahmoud Elsawy, MD, MSc

26–33
- PDF (en)
- PDF (fr)
Tailoring therapy in Waldenström Macroglobulinemia

Diego Villa, MD, MPH, FRCPC

14–19
- PDF (en)
- PDF (fr)
With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL)

Versha Banerji, MD, FRCPC

34–38
- PDF (en)
- PDF (fr)
Multiple myeloma management: What comes after lenalidomide-based therapy?

Martha Louzada, MD, MSc

21–24
- PDF (en)
- PDF (fr)
Immunotherapy in Hodgkin lymphoma Current and evolving roles

John Kuruvilla, MD, FRCPC

8–12
- PDF (en)
- PDF (fr)